Clinical innovation The Clatterbridge Cancer Centre is actively advancing personalized cancer therapies, including gene therapies, immunotherapies, and a bespoke cancer vaccine program in collaboration with the University of Liverpool and Theresa trials. This signals opportunities for partnerships, contract research, and supply of specialized biotech services and materials.

Multi-site scale With three main sites, four systemic therapy sites, and 15 outpatient centres plus in-community care, the organisation represents a sizable NHS provider with distributed operations. This creates potential for integrated service platforms, remote monitoring solutions, radiology and chemotherapy workflow software, and scalable medical technology deployments.

Proton therapy As the UK’s only facility providing low-energy proton beam therapy for rare eye cancers, Clatterbridge has a unique capability that may require specialized equipment maintenance, vendor support, and training services, offering a niche upsell path for high-value capital and service contracts.

Digital backbone Implemented tech stack includes iCIMS, Power BI, Drupal, Osano, SQL Server, Cisco, Office 365 and New Relic, indicating a mature approach to HR, data analytics, web content, data privacy, networking, collaboration, and application performance monitoring. This alignment supports opportunities for cloud migrations, cybersecurity, data integration, and analytics platform enhancements.

Regional partnerships Strategic collaboration on the North West Regional Amyloidosis Service and ongoing clinical trials suggests opportunities to engage in joint research, trial management software, patient recruitment services, and shared-care pathways that could extend to data services, patient experience tools, and pharmacy/clinical support solutions.